In a double-blind randomized clinical trial, 79 non-insulin-dependent diabetic subjects with early retinopathy and open-angle glaucoma received orally either three 500-mg capsules of Doxium® (calcium dobesilate) daily for 6 months (41 patients) or three placebo capsules daily for the same period (38 patients). At the end of the study statistically significant differences in the Doxium group compared with the placebo group were recorded: intraocular pressure, visual field defects, surface area of retinal hemorrhages, and whole blood and plasma viscosity were reduced (p < 0.001). Coefficient of outflow facility and serum albumin concentration were increased (p < 0.001 and p < 0.02, respectively). These results suggest that increased whole blood viscosity is a risk factor for diabetic retinopathy and for glaucomatous optic nerve damage. They further suggest that Doxium reduces blood hyperviscosity and lowers intraocular pressure, with a beneficial effect on retinal state and visual fields.

Keywords:
Doxium®, Diabetic retinopathy, Glaucoma, Viscosity
This content is only available via PDF.
© 1991 S. Karger AG, Basel
1991
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.